Literature DB >> 27505901

Clinical Assessments as Predictors of Primary On-Road Outcomes in Parkinson's Disease.

Sherrilene Classen1, Jeffrey D Holmes2, Liliana Alvarez3, Katherine Loew2, Ashley Mulvagh2, Kayla Rienas2, Victoria Walton2, Wenqing He2.   

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder that affects fitness to drive. Research that has examined clinical predictors of fitness to drive in PD, using the on-road assessment as the gold standard, has generally used a dichotomous pass/fail decision. However, on-road assessments may also result in one of two additional outcomes (pass with recommendations, or fail-remediable). Individuals within these subgroups may benefit from interventions to improve their fitness to drive abilities. This study investigated clinical predictors that could be indicative of the pass, pass with recommendations, or fail-remediable categories for drivers with PD (N = 99). Trails B, Left Finger to Nose Test, and contrast sensitivity measures were identified as significant predictors for the pass, and pass with recommendations subgroups. No significant predictors were identified for the fail-remediable subgroup. Results from this study provide a foundation for clinicians to identify drivers who can benefit from recommendations to preserve their driving abilities.
© The Author(s) 2015.

Entities:  

Keywords:  Parkinson’s disease; assessment; driving

Mesh:

Year:  2015        PMID: 27505901     DOI: 10.1177/1539449215601118

Source DB:  PubMed          Journal:  OTJR (Thorofare N J)        ISSN: 1539-4492


  2 in total

Review 1.  Driving with a neurodegenerative disorder: an overview of the current literature.

Authors:  Milou Jacobs; Ellen P Hart; Raymund A C Roos
Journal:  J Neurol       Date:  2017-04-19       Impact factor: 4.849

2.  RCT protocol for driving performance in people with Parkinson's using autonomous in-vehicle technologies.

Authors:  Sherrilene Classen; Yuan Li; Wayne Giang; Sandra Winter; Jiajun Wei; Bhavana Patel; Mary Jeghers; Beth Gibson; Jason Rogers; Adolfo Ramirez-Zamora
Journal:  Contemp Clin Trials Commun       Date:  2022-06-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.